Best Agrolife FY26 Revenue at ₹1,257 Cr, PAT ₹9 Cr Amidst Raw Material Price Hikes
Best Agrolife reported FY26 revenue of ₹1,257 crore, down from ₹1,814 crore in FY25, with PAT at ₹9 crore (4% margin in FY25). Q4 FY26 saw revenue of ₹156 crore and a PAT loss of ₹37 crore. The company launched three patented formulations in FY26 and plans four more in FY27. OPEX reduced by 15% to ₹280 crore, and inventory decreased to ₹651 crore.
The announcement details significant financial performance changes, including revenue decline and increased losses, which are material for investors. The company's strategic responses, such as price increases and new product launches, also indicate a substantial impact on its future operations and market position.
The company's revenue, EBITDA, and PAT have declined significantly in Q4 FY26 and for the full fiscal year FY26 compared to the previous year, indicating a negative financial performance. Although the management highlights cost-saving measures and future product launches, the current financial results are unfavorable.
Best Agrolife Limited has released its financial results for the fiscal year ended March 31, 2026, alongside a corporate presentation. The company reported revenue from operations of ₹1,257 crore for FY26, a decrease from ₹1,814 crore in the previous fiscal year. The gross margin remained stable at approximately 30% for FY26, supported by operational discipline. However, EBITDA margin declined to 8% in FY26 from 11% in FY25, and the Profit After Tax (PAT) margin also saw a reduction from 4% to 1% in the same period.
In the fourth quarter of FY26, revenue from operations stood at ₹156 crore, down from ₹274 crore in Q4 FY25. The company reported a negative EBITDA of ₹27 crore and a PAT loss of ₹37 crore for Q4 FY26, compared to a gain of ₹4 crore and a loss of ₹22 crore, respectively, in the prior year's fourth quarter. The management attributed the challenging environment in Q4 FY26 to a sharp increase in raw material prices due to the Gulf conflict, which led to a strategic curtailment of sales, impacting potential revenues by approximately ₹50-70 crore.
To mitigate rising input costs, Best Agrolife implemented two rounds of price increases in April and May 2026, anticipating these actions will correct profitability. The company focused on operational discipline, working capital optimization, portfolio rationalization, channel engagement, and OPEX reduction. OPEX was reduced by 15% year-on-year to ₹280 crore in FY26 from ₹331 crore in FY25. Inventory levels were significantly reduced to ₹651 crore as of March 31, 2026, down from ₹773 crore in FY25 and ₹958 crore in FY24.
During FY26, Best Agrolife expanded its specialty and patented product portfolio by launching three patented formulations: BestmanTM, FetagenTM, and Shot DownTM. The company also strengthened its intellectual property by securing seven new patents covering insecticides, fungicides, herbicides, and its own patented Nano Urea. Looking ahead to FY27, the company plans to launch four additional patented products: FluzamTM, MidcotinTM, Cubax Power ExtraTM, and TrishankuTM.
The company's financial health shows a reduced loan balance and positive overall cash flow. Key financial ratios indicate a Debt to Equity ratio of 0.44 and a Net Debt to Equity ratio of 0.48 as of March 31, 2026. The Current Ratio stood at 1.53.
What to do with a filing like this
Best Agrolife Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Best Agrolife Limited. Read the original for the full detail.